Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Sagene Pharmaceuticals Inc.
DescriptionOral combination of selegiline, an MAO-B inhibitor, and a PDE-5 inhibitor
Molecular Target Monoamine oxidase B (MAO-B) ; Phosphodiesterase-5 (PDE-5)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentIND
Standard IndicationErectile dysfunction (ED)
Indication DetailsTreat erectile dysfunction (ED)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today